January 2011 -- Despite Biogen’s resolve to maintain its leading position in the MS market, rejection of Fampyra (dalfampridine) today and Novartis’s Gilenya (fingolimod) recommendation for European marketing authorization will deal another blow to its franchise, says independent analyst Datamonitor.
Dr Trung Huynh, healthcare analyst at Datamonitor, comments: “Gilenya’s recommendation comes as welcome news for European MS sufferers. However, the committee’s negative opinion of Fampyra is a surprise given that it was approved by the FDA.”
“Gilenya, which is widely regarded as a more convenient and effective alternative, will provide heavy competition for Biogen in the market and will lead to a decline in sales for the company. In the sort term though, Biogen will still see sales figures grow as a result of recent price rises on its leading therapies Avonex and Tysabri”
“Novartis is now set to become the leading player in the multibillion dollar market and can expect to generate annual revenues of around $2.5 billion by the end of the decade. However, Biogen’s strong pipeline suggest the company with not go down with a fight” concludes Dr Huynh.
Trung Huynh is available for comment.
To arrange an interview or for further details regarding this release please contact Joe Dixonin the Datamonitor press office on + 44 (0)161 238 4083, or email firstname.lastname@example.org
The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world’s leading companies in making better strategic and operational decisions.